	US 12,410,238 B2
	Monoclonal antibodies against JC virus
Thomas Moran, New York, NY (US); Thomas Kraus, New York, NY (US); J. Andrew Duty, New York, NY (US); and Domenico Tortorella, New York, NY (US)
Assigned to ICAHN School of Medicine at Mount Sinai, New York, NY (US)
Appl. No. 17/620,496
Filed by Icahn School of Medicine at Mount Sinai, New York, NY (US)
PCT Filed Jun. 19, 2020, PCT No. PCT/US2020/038708 § 371(c)(1), (2) Date Dec. 17, 2021, PCT Pub. No. WO2020/257633, PCT Pub. Date Dec. 24, 2020.
Claims priority of provisional application 62/863,433, filed on Jun. 19, 2019.
Prior Publication US 2022/0356228 A1, Nov. 10, 2022
Int. Cl. C07K 16/08 (2006.01); A61P 25/28 (2006.01); A61P 31/20 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/08 (2013.01) [C12N 15/63 (2013.01); A61P 25/28 (2018.01); A61P 31/20 (2018.01); C07K 16/084 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

28 Claims

1. An antibody or antigen-binding fragment thereof which binds to the John Cunningham virus (JCV), the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region;

wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3; and wherein:

(a) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:5, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(b) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:1, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(c) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:25, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(d) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:26, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(e) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:14, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:37, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(f) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:4, CDR2H comprises SEQ ID NO:15, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;

(g) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:29, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO: 48;

(h) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:30, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO: 49;

(i) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:18, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AAS, and CDR3L comprises SEQ ID NO:51;

(j) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:19, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AVS, and CDR3L comprises SEQ ID NO:52;

(k) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:11, CDR2H comprises SEQ ID NO:22, CDR3H comprises SEQ ID NO:35, CDR1L comprises SEQ ID NO:44, CDR2L comprises the sequence GTS, and CDR3L comprises SEQ ID NO:55;

(l) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:9, CDR2H comprises SEQ ID NO:20, CDR3H comprises SEQ ID NO:33, CDR1L comprises SEQ ID NO:42, CDR2L comprises the sequence WAS, and CDR3L comprises SEQ ID NO:53; or

(m) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:10, CDR2H comprises SEQ ID NO:21, CDR3H comprises SEQ ID NO:34, CDR1L comprises SEQ ID NO:43, CDR2L comprises the sequence GAS, and CDR3L comprises SEQ ID NO:54.